# BPI

## Overview
Bactericidal/permeability-increasing protein (BPI) is a critical component of the human immune system, encoded by the BPI gene. This protein is primarily found in the cytoplasmic granules of neutrophils and plays a pivotal role in the innate immune response against Gram-negative bacteria. BPI is categorized as an antimicrobial protein due to its ability to bind to lipopolysaccharides (LPS) on bacterial membranes, leading to bacterial lysis and neutralization of endotoxins (Theprungsirikul2021Killing; Beamer1998The). Structurally, BPI is characterized by a boomerang-shaped molecular configuration with two lipid-binding domains, which are essential for its function in lipid transfer and interaction with bacterial membranes (Beamer1998The). Beyond its bactericidal properties, BPI also exhibits anti-inflammatory effects by inhibiting endotoxin-induced inflammation, thereby modulating immune responses (Schultz2007The). The gene and its protein product are of significant clinical interest due to their involvement in various diseases, including chronic obstructive pulmonary disease and inflammatory bowel disease, where mutations and autoantibodies against BPI have been implicated (Chen2012The; Akın2011Association).

## Structure
The bactericidal/permeability-increasing protein (BPI) is characterized by a unique boomerang-shaped molecular structure, consisting of two similar domains connected by a proline-rich linker. The primary structure of BPI includes 456 amino acid residues, with 102 of these being conserved across the BPI/LBP family, indicating their importance in function and structural integrity (Beamer1998The). The secondary structure is organized into two main domains: the NH2-terminal domain (residues 1-229) and the COOH-terminal domain (residues 251-456), each forming a barrel-like structure composed of two α-helices and a twisted β-sheet (Beamer1997Crystal; Beamer1998The).

The tertiary structure is stabilized by a conserved disulfide bond between Cys132 and Cys175, anchoring helix B to the β-sheet of barrel N (Beamer1998The). The protein also features two apolar lipid-binding pockets, each capable of binding a phospholipid molecule, which are crucial for its function in lipid transfer and interaction with lipopolysaccharides (Beamer1997Crystal; Beamer1998The). The quaternary structure is not explicitly detailed, but the presence of lipid-binding pockets suggests a functional arrangement (Beamer1998The). BPI undergoes post-translational modifications, such as glycosylation, which can affect its function.

## Function
The bactericidal/permeability-increasing protein (BPI) is a crucial component of the innate immune system, primarily found in the cytoplasmic granules of polymorphonuclear neutrophils. BPI plays a significant role in targeting Gram-negative bacteria by binding to lipopolysaccharides (LPS) on their outer membranes, leading to bacterial membrane disruption and neutralization of endotoxins (Theprungsirikul2021Killing; Beamer1998The). This protein is characterized by its high positive charge, particularly in the NH2-terminal domain, which facilitates electrostatic interactions with the negatively charged LPS, contributing to its bactericidal activity (Beamer1998The).

BPI is also expressed in human mucosal epithelial cells, where it contributes to bacterial killing and endotoxin neutralization, particularly against BPI-sensitive bacteria like Salmonella typhimurium (Canny2002Lipid). It is localized predominantly in the epithelium of the esophagus and colon, suggesting a role in maintaining mucosal integrity and defense (Canny2002Lipid). BPI's opsonic effects enhance phagocytosis of bacteria by neutrophils, linking innate and adaptive immune responses (Schultz2007The). In addition to its bactericidal functions, BPI also plays an anti-inflammatory role by inhibiting endotoxin-induced inflammation (Schultz2007The).

## Clinical Significance
Mutations and alterations in the BPI gene are associated with several diseases and conditions. In chronic obstructive pulmonary disease (COPD), a specific BPI mutation, the PstI (T→C) polymorphism in intron 5, is linked to an increased risk of developing the disease. COPD patients also exhibit significantly lower plasma levels of BPI, suggesting that decreased BPI production or release may contribute to airflow obstruction in smokers (Chen2012The).

In inflammatory bowel disease (IBD), particularly Crohn's disease and ulcerative colitis, the BPI Lys216Glu polymorphism is associated with a genetic predisposition to these conditions. This polymorphism may alter pathogen recognition by the innate immune system, potentially leading to gut dysbiosis (Theprungsirikul2021Killing; Akın2011Association).

Autoantibodies against BPI are present in various conditions, including cystic fibrosis (CF), bronchiectasis, and COPD, where they are associated with poor lung function. These autoantibodies can impair BPI's opsonic and antibiotic actions, contributing to chronic inflammation and disease severity (Schultz2007The; Schinke2004Autoantibodies).

In TAP deficiency, BPI-ANCA (anti-neutrophil cytoplasmic antibodies against BPI) are linked to increased susceptibility to Gram-negative bacterial infections, particularly affecting the respiratory tract (SCHULTZ2003BPI–ANCA).

## Interactions
Bactericidal/permeability-increasing protein (BPI) interacts with lipopolysaccharides (LPS) on Gram-negative bacteria, forming high-affinity complexes that neutralize endotoxin activity. BPI competes with lipopolysaccharide-binding protein (LBP) for binding to LPS, inhibiting LBP-dependent endotoxin transfer to CD14/MD-2/TLR4, thereby preventing cell activation by endotoxin (Tobias1997Lipopolysaccharide; Schultz2007The). Unlike LBP, BPI does not promote LPS delivery to CD14, resulting in reduced cell activation (Iovine2002The). BPI's interactions with LPS are primarily driven by its N-terminal domain, which is responsible for binding endotoxin, while the C-terminal domain targets BPI-coated endotoxin-rich particles to host cells (Schultz2007The).

BPI also interacts with other proteins, such as defensin and cathelicidin antimicrobial peptides, enhancing its antibacterial activity (Canny2008Bactericidalpermeabilityincreasing). It can promote CD14-independent interactions with host cells and facilitate the uptake of endotoxin and outer membrane blebs by dendritic cells, suggesting a role in antigen presentation (Schultz2007The). BPI's ability to form stable complexes with LPS, compared to LBP, influences its role in modulating immune responses (Iovine2002The). These interactions highlight BPI's critical function in the immune response against Gram-negative bacterial infections.


## References


[1. (Beamer1998The) Lesa J. Beamer, Stephen F. Carroll, and David Eisenberg. The bpi/lbp family of proteins: a structural analysis of conserved regions. Protein Science, 7(4):906–914, April 1998. URL: http://dx.doi.org/10.1002/pro.5560070408, doi:10.1002/pro.5560070408. This article has 113 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/pro.5560070408)

[2. (Akın2011Association) Hakan Akın, Gülgün Tahan, Filiz Türe, Fatih Eren, Özlen Atuğ, Veysel Tahan, İsmail Hamzaoğlu, Neşe İmeryüz, Nurdan Tözün, and Hulya Over Hamzaoglu. Association between bactericidal/permeability increasing protein (bpi) gene polymorphism (lys216glu) and inflammatory bowel disease. Journal of Crohn’s and Colitis, 5(1):14–18, February 2011. URL: http://dx.doi.org/10.1016/j.crohns.2010.08.008, doi:10.1016/j.crohns.2010.08.008. This article has 11 citations.](https://doi.org/10.1016/j.crohns.2010.08.008)

[3. (Theprungsirikul2021Killing) Jomkuan Theprungsirikul, Sladjana Skopelja-Gardner, and William F.C. Rigby. Killing three birds with one bpi: bactericidal, opsonic, and anti-inflammatory functions. Journal of Translational Autoimmunity, 4:100105, 2021. URL: http://dx.doi.org/10.1016/j.jtauto.2021.100105, doi:10.1016/j.jtauto.2021.100105. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jtauto.2021.100105)

[4. (Beamer1997Crystal) Lesa J. Beamer, Stephen F. Carroll, and David Eisenberg. Crystal structure of human bpi and two bound phospholipids at 2.4 angstrom resolution. Science, 276(5320):1861–1864, June 1997. URL: http://dx.doi.org/10.1126/science.276.5320.1861, doi:10.1126/science.276.5320.1861. This article has 270 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.276.5320.1861)

[5. (Tobias1997Lipopolysaccharide) Peter S. Tobias, Katrin Soldau, Nicole M. Iovine, Peter Elsbach, and Jerrold Weiss. Lipopolysaccharide (lps)-binding proteins bpi and lbp form different types of complexes with lps. Journal of Biological Chemistry, 272(30):18682–18685, July 1997. URL: http://dx.doi.org/10.1074/jbc.272.30.18682, doi:10.1074/jbc.272.30.18682. This article has 95 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.272.30.18682)

[6. (Iovine2002The) Nicole Iovine, Joshua Eastvold, Peter Elsbach, Jerrold P. Weiss, and Theresa Lee Gioannini. The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes. Journal of Biological Chemistry, 277(10):7970–7978, March 2002. URL: http://dx.doi.org/10.1074/jbc.m109622200, doi:10.1074/jbc.m109622200. This article has 74 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m109622200)

[7. (Schultz2007The) Hendrik Schultz and Jerrold P. Weiss. The bactericidal/permeability-increasing protein (bpi) in infection and inflammatory disease. Clinica Chimica Acta, 384(1–2):12–23, September 2007. URL: http://dx.doi.org/10.1016/j.cca.2007.07.005, doi:10.1016/j.cca.2007.07.005. This article has 92 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cca.2007.07.005)

[8. (SCHULTZ2003BPI–ANCA) H SCHULTZ, S SCHINKE, J WEISS, V CERUNDOLO, W L GROSS, and S GADOLA. Bpi–anca in transporter associated with antigen presentation (tap) deficiency: possible role in susceptibility to gram-negative bacterial infections. Clinical and Experimental Immunology, 133(2):252–259, July 2003. URL: http://dx.doi.org/10.1046/j.1365-2249.2003.02197.x, doi:10.1046/j.1365-2249.2003.02197.x. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1046/j.1365-2249.2003.02197.x)

[9. (Chen2012The) Chiung-Zuei Chen, Chih-Ying Ou, Ru-Hsueh Wang, Cheng-Hung Lee, Chien-Chung Lin, Han-Yu Chang, and Tzuen-Ren Hsiue. The role of bactericidal/permeability-increasing protein in men with chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 9(2):197–202, March 2012. URL: http://dx.doi.org/10.3109/15412555.2011.654143, doi:10.3109/15412555.2011.654143. This article has 12 citations.](https://doi.org/10.3109/15412555.2011.654143)

[10. (Canny2002Lipid) Geraldine Canny, Ofer Levy, Glenn T. Furuta, Sailaja Narravula-Alipati, Richard B. Sisson, Charles N. Serhan, and Sean P. Colgan. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (bpi) in human mucosal epithelia. Proceedings of the National Academy of Sciences, 99(6):3902–3907, March 2002. URL: http://dx.doi.org/10.1073/pnas.052533799, doi:10.1073/pnas.052533799. This article has 235 citations.](https://doi.org/10.1073/pnas.052533799)

[11. (Canny2008Bactericidalpermeabilityincreasing) Geraldine Canny and Ofer Levy. Bactericidal/permeability-increasing protein (bpi) and bpi homologs at mucosal sites. Trends in Immunology, 29(11):541–547, November 2008. URL: http://dx.doi.org/10.1016/j.it.2008.07.012, doi:10.1016/j.it.2008.07.012. This article has 69 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.it.2008.07.012)

[12. (Schinke2004Autoantibodies) Susanne Schinke, Klaus Fellermann, Karen Herlyn, Philipp H. Reichel, Rilana Fundke, Eduard F. Stange, Wolfgang L. Gross, and Hendrik Schultz. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflammatory Bowel Diseases, 10(6):763–770, November 2004. URL: http://dx.doi.org/10.1097/00054725-200411000-00011, doi:10.1097/00054725-200411000-00011. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1097/00054725-200411000-00011)